SCHEMBL736532

SCHEMBL736532

COc1ccc2c(c1)C(=O)OC21CCNCC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AVPR1A P37288 3/20 0.53
HRH3 Q9Y5N1 2/20 0.48
NPY5R Q15761 3/20 0.47
HTR2C P28335 2/20 0.44
PPIB P23284 1/20 0.44
RYR2 Q92736 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2B P41595 1/20 0.41
OPRD1 P41143 1/20 0.41
KCNH2 Q12809 1/20 0.41
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MALT1 Q9UDY8 2/20 0.40
PDE7A Q13946 1/20 0.39
SIGMAR1 Q99720 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20955204 0.99 AVPR1A (0.52) AVPR1AHRH3NPY5RHTR2CPPIB
SCHEMBL736508 0.89 AVPR1A (0.53) AVPR1AHRH3NPY5RHTR2CPPIB
Hydrochloric Acid SCHEMBL20955425 0.88 AVPR1A (0.52) AVPR1AHRH3NPY5RHTR2CPPIB
SCHEMBL12568900 0.82 HRH3 (0.55) AVPR1AHRH3NPY5RPPIBALDH1A1
SCHEMBL11829309 0.82 AVPR1A (0.63) AVPR1AHRH3NPY5RPPIBSIGMAR1
SCHEMBL4369332 0.81 AKR1A1 (0.41) AVPR1AHRH3PDE3BPDE3ASIGMAR1
SCHEMBL11832778 0.80 AVPR1A (0.50) AVPR1ANPY5RALDH1A1MALT1SIGMAR1
SCHEMBL326429 0.80 MAOB (0.52) ALDH1A1SIGMAR1
SCHEMBL12568929 0.79 HRH3 (0.50) AVPR1AHRH3NPY5RPPIBMALT1
SCHEMBL12568933 0.79 HRH3 (0.50) AVPR1AHRH3NPY5RPPIBMALT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066378-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2025-02-27 US disclosed
US-12162887-B2 Spiro-oxazolones HOFFMANN-LA ROCHE INC. (US) 2024-12-10 US disclosed
US-20230106150-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2023-04-06 US disclosed
US-11578077-B2 Spiro-oxazolones HOFFMANN-LA ROCHE INC. (US) 2023-02-14 US disclosed
US-11414429-B2 Compound or pharmaceutically acceptable salt thereof RIKEN (JP) 2022-08-16 US disclosed
US-20200172554-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF RIKEN (JP) 2020-06-04 US disclosed
US-20200039997-A1 SPIRO-OXAZOLONES HOFFMANN-LA ROCHE INC. (US) 2020-02-06 US disclosed
US-10479796-B2 Spiro-oxazolones HOFFMAN-LA ROCHE INC. (US) 2019-11-19 US disclosed
EP-3107916-B1 SPIRO-OXAZOLONES HOFFMANN LA ROCHE (CH) 2019-03-20 EP disclosed
EP-3083633-B1 SPIRO-OXAZOLONES HOFFMANN LA ROCHE (CH) 2017-11-29 EP disclosed
US-20080161304-A1 Spiro-piperidine derivatives HOFFMANN-LA ROCHE, INC. 2008-07-03 US disclosed
US-20080153861-A1 SPIROPIPERIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 US disclosed
US-20080153862-A1 SPIROPIPERIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 US disclosed
US-20080153863-A1 SPIROPIPERIDINE DERIVATIVES HOFFMAN-LA ROCHE INC. 2008-06-26 US disclosed
US-20080146557-A1 INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS BISSANTZ CATERINA 2008-06-19 US disclosed
EP-1904477-A1 INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
EP-1892241-A1 NOVEL PIPERIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-02-27 EP disclosed
US-7332501-B2 Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2008-02-19 US disclosed
US-20070027173-A1 Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 2007-02-01 US disclosed
WO-2007006688-A1 INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153863-A1 SPIROPIPERIDINE DERIVATIVES AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885HRH3 522/4885NPY5R 22/4885
US-20080153861-A1 SPIROPIPERIDINE DERIVATIVES AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885HRH3 522/4885NPY5R 22/4885
US-20080161304-A1 Spiro-piperidine derivatives AVPR1A, AVPR1B, ADRA1A AVPR1A 1/4885HRH3 433/4885NPY5R 53/4885
US-20070027173-A1 Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists AVPR1A, AVPR2, AVPR1B AVPR1A 1/4885HRH3 729/4885NPY5R 200/4885
US-11414429-B2 Compound or pharmaceutically acceptable salt thereof DPP8, DPP7, AZI2 AVPR1A 168/4885HRH3 3405/4885NPY5R 247/4885
US-20200172554-A1 NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DPP8, DPP7, AZI2 AVPR1A 158/4885HRH3 3468/4885NPY5R 259/4885
US-12162887-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885HRH3 980/4885NPY5R 162/4885
US-11578077-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885HRH3 980/4885NPY5R 162/4885
US-20250066378-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885HRH3 980/4885NPY5R 162/4885
US-20200039997-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885HRH3 980/4885NPY5R 162/4885
US-20080153862-A1 SPIROPIPERIDINE DERIVATIVES AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885HRH3 522/4885NPY5R 22/4885
US-20080146557-A1 INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS AVPR1A, AVPR2, OXTR AVPR1A 1/4885HRH3 460/4885NPY5R 79/4885
US-20230106150-A1 SPIRO-OXAZOLONES AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885HRH3 980/4885NPY5R 162/4885
US-10479796-B2 Spiro-oxazolones AVPR1A, AVPR1B, AVPR2 AVPR1A 1/4885HRH3 980/4885NPY5R 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.